Renata expands UK portfolio with new hydrocortisone dose

Renata PLC has launched Hydrocortisone 5mg Tablets in the United Kingdom, further strengthening its presence in the corticosteroid therapy segment and expanding access to essential endocrine medicines.

The product is manufactured at Renata's Mirpur Potent Facility, which is certified by both the UK MHRA and EU GMP standards.

The newly introduced 5mg strength is indicated for replacement therapy in patients with adrenocortical insufficiency. It offers clinicians greater flexibility in dose adjustment, helping to mimic the body's natural cortisol rhythm and supporting improved disease management and treatment outcomes.

Renata is among the few companies offering this dosage strength in the UK market, reinforcing its commitment to patient-centred therapeutic solutions for chronic and critical illnesses.

The launch also underscores the company's growing role as a reliable partner in patient care in the UK and other regulated markets.